The Birth of CRISPR Inc.

doi:10.1126/science.355.6326.680

Paper

The Birth of CRISPR Inc.

Published Feb 17, 2017 · Jon Cohen

Science

16

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Just 5 years ago, the community of researchers studying CRISPR, the powerful new genome editing tool, was small. When the first inklings that CRISPR could become a big business emerged, leading scientists expected to work together. But the attempt at unity collapsed—with a good deal of noise and dust. As the science grew even more compelling and venture capital (VC) beckoned, the jockeying to start CRISPR companies became intense. The research community was rent apart by concerns about intellectual property, academic credit, Nobel Prize dreams, geography, media coverage, egos, personal profit, and loyalty. A billion dollars poured into what might be called CRISPR Inc. from VC firms, pharmaceutical companies, and public stock offerings. And the companies and the academic license holders faced each other down in a battle royale over patents.

Study Snapshot

CRISPR Inc. has become a multibillion-dollar company, fueled by VC funding, pharmaceutical companies, and academic license holders, battling over patents and intellectual property.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

The Birth of CRISPR Inc.

References

Citations